A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518465-10-00

Acronym

VT-001-0060

Enrollment

107

Registered

2025-09-08

Start date

2025-12-12

Completion date

Unknown

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Autoimmune Glomerular Diseases

Brief summary

Change from baseline in UPCR at Week 36

Detailed description

Changes from baseline in Gd-IgA1 (IgAN) or anti-PLA2R (pMN), Changes from baseline in eGFR (CKD-EPI) at Weeks 36 and 52, Change from baseline in UPCR at Week 52 (IgAN cohorts), or Weeks 12, 24, and 52 (pMN and NS cohorts), Serum concentration of atacicept throughout the entire study, Proportion of participants achieving proteinuric responses defined in Table 3 at Weeks 24, 36, and 52

Interventions

DRUGAtacicept

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in UPCR at Week 36	—

Secondary

Measure	Time frame
Changes from baseline in Gd-IgA1 (IgAN) or anti-PLA2R (pMN), Changes from baseline in eGFR (CKD-EPI) at Weeks 36 and 52, Change from baseline in UPCR at Week 52 (IgAN cohorts), or Weeks 12, 24, and 52 (pMN and NS cohorts), Serum concentration of atacicept throughout the entire study, Proportion of participants achieving proteinuric responses defined in Table 3 at Weeks 24, 36, and 52	—

Countries

Belgium, France, Germany, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026